Growth Metrics

Gilead Sciences (GILD) Cost of Revenue (2016 - 2026)

Gilead Sciences filings provide 17 years of Cost of Revenue readings, the most recent being $1.6 billion for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 2.72% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 billion, a 0.27% change, with the full-year FY2025 number at $6.2 billion, changed 0.27% from a year prior.
  • Cost of Revenue hit $1.6 billion in Q4 2025 for Gilead Sciences, up from $1.6 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $2.6 billion in Q4 2021 to a low of $1.2 billion in Q3 2021.
  • Median Cost of Revenue over the past 5 years was $1.5 billion (2025), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Cost of Revenue: surged 87.91% in 2021 and later crashed 46.86% in 2022.
  • Gilead Sciences' Cost of Revenue stood at $2.6 billion in 2021, then crashed by 46.86% to $1.4 billion in 2022, then soared by 49.71% to $2.1 billion in 2023, then fell by 24.35% to $1.6 billion in 2024, then increased by 2.72% to $1.6 billion in 2025.
  • The last three reported values for Cost of Revenue were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.